Home Tags PcALCL

Tag: pcALCL

Breakthrough Therapy Designation for Brentuximab Vedotin in CD30-expressing Mycosis Fungoides and...

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for brentuximab vedotin (Adcetris®; Seattle Genetics) for the treatment of patients with...

Seattle Genetics Completes Enrollment for Phase III Trial Designed to Evaluate...

Seattle Genetics and its collaborator, Takeda Pharmaceutical, have completed patient enrollment in the open label, phase III ALCANZA (NCT01578499) clinical trial.  This randomized trial is...

X